Health Bulletin

The long-term COVID concern for immune compromised Americans: ‘I’m at risk’

The long-term COVID concern for immune compromised Americans: 'I'm at risk'

In the U.S., immunocompromised people make up more than 40% of serious breakthrough COVID infections

As pandemic restrictions are lifted across the U.S., millions of immunocompromised Americans feel they’re in limbo, unsure about how safe they really are.

It’s estimated that 7 million Americans — 2.7% of the population — are immunocompromised, though they make up between 40-44% of serious breakthrough COVID infections, according to the Centers for Disease Control and Prevention. People with organ transplants, cancer, HIV, autoimmune diseases and other immunity-compromising conditions are considered at greater risk.

Mike Olsen, a lung transplant recipient, told Fox News he continues to live life on high alert because of his weakened immune system.

“People can still spread the virus to someone like me, who’s immune suppressed. They don’t realize they can,” Olsen said. “When they take off their masks that puts me in a predicament where I have to be more extra careful now in public.”

Vaccines would ordinarily reduce the risk of infection and severe illness, but many immunocompromised people barely respond to the COVID shots, according to Dr. Abhijit Duggal, a pulmonary medicine specialist at the Cleveland Clinic. Some people with autoimmune disorders cannot be fully vaccinated because their initial doses led to severe flare-ups of their normal symptoms.

“They have a higher risk of getting sick enough to come to the hospital more often, needing the ICU more often,” Duggal said. “I know it’s difficult two years into the pandemic. But because we are unsure about the risk for these populations, we need to be mindful that we protect them.”

Feeling unprotected, several of Duggal’s patients have lived far more isolated lives during the pandemic than most people, Duggal told Fox News.

New immune therapies could offer hope to the immune compromised. Evusheld, a two-antibody cocktail from AstraZeneca, can reduce the risk of developing COVID. And while it is less effective against COVID’S omicron variant, it is still protective. The FDA issued an emergency use authorization for the cocktail to prevent infections in immunocompromised people.

However, these drugs are in short supply. The government has ordered only 1.7 million doses of Evusheld and distributed 400,000. The U.S. has at least 7 million immunocompromised adults.

What is your reaction?

In Love
Not Sure

You may also like

Comments are closed.